- Home
- TYGO vs NRXP Comparison
TYGO vs NRXP Comparison
Compare TYGO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- NRXP
- Stock Information
- Founded
- TYGO 2007
- NRXP 2015
- Country
- TYGO United States
- NRXP United States
- Employees
- TYGO N/A
- NRXP N/A
- Industry
- TYGO Semiconductors
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- NRXP Health Care
- Exchange
- TYGO Nasdaq
- NRXP Nasdaq
- Market Cap
- TYGO 63.2M
- NRXP 51.3M
- IPO Year
- TYGO N/A
- NRXP N/A
- Fundamental
- Price
- TYGO $0.96
- NRXP $2.28
- Analyst Decision
- TYGO Buy
- NRXP Strong Buy
- Analyst Count
- TYGO 3
- NRXP 3
- Target Price
- TYGO $3.00
- NRXP $31.67
- AVG Volume (30 Days)
- TYGO 59.0K
- NRXP 464.9K
- Earning Date
- TYGO 02-11-2025
- NRXP 03-27-2025
- Dividend Yield
- TYGO N/A
- NRXP N/A
- EPS Growth
- TYGO N/A
- NRXP N/A
- EPS
- TYGO N/A
- NRXP N/A
- Revenue
- TYGO $54,014,000.00
- NRXP N/A
- Revenue This Year
- TYGO $54.22
- NRXP N/A
- Revenue Next Year
- TYGO $54.45
- NRXP N/A
- P/E Ratio
- TYGO N/A
- NRXP N/A
- Revenue Growth
- TYGO N/A
- NRXP N/A
- 52 Week Low
- TYGO $0.76
- NRXP $1.10
- 52 Week High
- TYGO $1.85
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- TYGO 46.31
- NRXP 38.85
- Support Level
- TYGO $0.90
- NRXP $2.80
- Resistance Level
- TYGO $1.04
- NRXP $3.07
- Average True Range (ATR)
- TYGO 0.08
- NRXP 0.29
- MACD
- TYGO -0.01
- NRXP -0.10
- Stochastic Oscillator
- TYGO 30.00
- NRXP 2.52
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.